

E1
cont

- b) assaying for binding of the test agent to the PKC ϵ ; and
- c) if binding is detected, selecting the test agent as a potential modulator of anxiety.

E2

64. (Amended) A method of screening for an agent that modulates anxiety, said method comprising:

- a) exposing a functional PKC ϵ , or a cell or cell lysate comprising a functional PKC ϵ , to a test agent;
- b) determining whether the test agent inhibits PKC ϵ ; and
- c) if the test agent inhibits PKC ϵ , selecting the test agent as a potential modulator of anxiety.

E3

68. (Amended) The screening method of claim 64 wherein determining whether the test agent inhibits PKC ϵ comprises measuring an activity of PKC ϵ in the presence of the test agent.

E4

70. (Amended) The screening method of claim 64 wherein determining whether the test agent inhibits PKC ϵ comprises measuring the ability of the test agent to selectively inhibit PKC ϵ activity.

71. (Amended) The screening method of claim 64 additionally comprising:

- c) administering to an animal a test agent that inhibits the activity of PKC ϵ ; and
- d) measuring one or more indicators of anxiety to determine whether the test agent modulates anxiety in the animal.

E5

76. (Amended) A method of screening for an agent that modulates anxiety, said method comprising:

- a) selecting an agent that inhibits PKC ϵ as a test agent;
- b) administering the test agent to an animal; and
- c) measuring one or more indicators of anxiety to determine whether the test agent modulates anxiety in the animal.